1. Home
  2. YOOV vs SPRO Comparison

YOOV vs SPRO Comparison

Compare YOOV & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concorde International Group Ltd Class A Ordinary Shares

YOOV

Concorde International Group Ltd Class A Ordinary Shares

N/A

Current Price

$0.59

Market Cap

158.7M

ML Signal

N/A

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.12

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YOOV
SPRO
Founded
N/A
2013
Country
Singapore
United States
Employees
109
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
158.7M
156.3M
IPO Year
2025
2017

Fundamental Metrics

Financial Performance
Metric
YOOV
SPRO
Price
$0.59
$2.12
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.8M
1.6M
Earning Date
N/A
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$0.36
$1.80
52 Week High
$1.11
$3.08

Technical Indicators

Market Signals
Indicator
YOOV
SPRO
Relative Strength Index (RSI) 56.35 38.90
Support Level $0.52 $1.98
Resistance Level $0.79 $2.45
Average True Range (ATR) 0.14 0.10
MACD 0.00 -0.00
Stochastic Oscillator 29.52 34.48

Price Performance

Historical Comparison
YOOV
SPRO

About YOOV Concorde International Group Ltd Class A Ordinary Shares

Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. The Majority revenue is generated from Security Services.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: